TIDMDXRX
RNS Number : 4993U
Diaceutics PLC
06 April 2021
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, announces the issue of share options over ordinary shares
of GBP0.002 each in the Company ("Share Options") to certain
Directors, members of the Company's senior management team and
other key staff, pursuant to the Company's Employee Share Option
Plan ("ESOP"). These awards are made in accordance with the
Company's long term incentive plan.
Share Options were granted as follows:
Name Number of Share Total no. of % of existing Effective
Options granted ordinary shares issued share Grant date
under option capital
post grant
Peter Keeling, CEO 73,542 253,542 0.30% 1 April 2021
---------------- ---------------- ------------- --------------
Philip White, CFO 64,154 244,154 0.29% 1 April 2021
---------------- ---------------- ------------- --------------
Ryan Keeling, CIO 64,154 244,154 0.29% 1 April 2021
---------------- ---------------- ------------- --------------
Damian Thornton, COO
and PDMR 64,062 166,766 0.20% 1 April 2021
---------------- ---------------- ------------- --------------
Jordan Clark, CCO and
PDMR 46,003 122,117 0.15% 1 April 2021
---------------- ---------------- ------------- --------------
Susanne Munksted, PDMR 45,475 116,147 0.14% 1 April 2021
---------------- ---------------- ------------- --------------
Other employees (36
persons) 534,581 869,811 1.03% 1 April 2021
---------------- ---------------- ------------- --------------
The Share Options vest on a sliding scale up to 100%, after
three years from the date of grant (the "Performance Period"),
subject to the satisfaction of certain performance criteria. The
performance criteria is based upon the growth in Total Shareholder
Return, measured using the average mid-market closing share price
in the month immediately before the end of the Performance Period,
plus any dividends declared and paid during the Performance Period.
The growth in TSR will be measured against a base share price of
102.67p, being the average mid-market closing share price in the
three days prior to 1 April 2021, when the options were issued. The
exercise price of the Share Options is GBP0.002 per share which
equates to the nominal value of the shares.
Following this grant, the total number of share options
outstanding in the Company is 2,016,687, representing approximately
2.4% of its current issued share capital of 84,063,923.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0)207 397 8900
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - our Proprietary
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. Diaceutics has
worked on every precision medicine brought to market and provides
solutions to 36 of the world's leading pharmaceutical companies.
DXRX - the Diagnostic Network (R) provides unrivalled access to
deep analysis and insights from the world's largest repository of
diagnostic testing data on one secure platform.
www.diaceutics.com
About DXRX - The Diagnostic Network(R)
DXRX is Diaceutics' proprietary diagnostic network for precision
medicine. DXRX is an end-to-end solution for the development and
commercialisation of Precision Medicine diagnostics. The platform
enables a vibrant marketplace where all stakeholders in Precision
Medicine come to find trusted partners and collaborations in a
secure, standardised way. DXRX provides access to a pipeline of
global diagnostic testing data on one secure platform.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name Peter Keeling
-----------------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------------
a. Position/Status Chief Executive Officer
------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of GBP0.002
the financial each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- -----------------------------
Exercise price
of GBP0.002
per share 73,542
------------------------------------------------------------------------- -----------------
e. Date of the transaction 1 April 2021
------------------------------------- -----------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name Philip White
-----------------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------------
a. Position/Status Chief Financial Officer
------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of GBP0.002
the financial each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- -----------------------------
Exercise price
of GBP0.002
per share 64,154
------------------------------------------------------------------------- -----------------
e. Date of the transaction 1 April 2021
------------------------------------- -----------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name Ryan Keeling
-----------------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------------
a. Position/Status Chief Innovation Officer
------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of GBP0.002
the financial each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- -----------------------------
Exercise price
of GBP0.002
per share 64,154
------------------------------------------------------------------------- -----------------
e. Date of the transaction 1 April 2021
------------------------------------- -----------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name Damian Thornton
-----------------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------------
a. Position/Status Chief Operating Officer
------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of GBP0.002
the financial each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- -----------------------------
Exercise price
of GBP0.002
per share 64,062
------------------------------------------------------------------------- -----------------
e. Date of the transaction 1 April 2021
------------------------------------- -----------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name Jordan Clark
-----------------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------------
a. Position/Status Chief Technology Officer
------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of GBP0.002
the financial each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- -----------------------------
Exercise price
of GBP0.002
per share 46,003
------------------------------------------------------------------------- -----------------
e. Date of the transaction 1 April 2021
------------------------------------- -----------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name Susanne Munksted
-----------------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------------
a. Position/Status Managing Director and PDMR
------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of GBP0.002
the financial each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- -----------------------------
Exercise price
of GBP0.002
per share 45,475
------------------------------------------------------------------------- -----------------
e. Date of the transaction 1 April 2021
------------------------------------- -----------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBGGDSCGGDGBL
(END) Dow Jones Newswires
April 06, 2021 06:12 ET (10:12 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
